Literature DB >> 35586439

Indazole and Benzoisoxazole Compounds as Dihydroorotate Dehydrogenase Inhibitors for Treating Acute Myelogenous Leukemia.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35586439      PMCID： PMC9109513          DOI： 10.1021/acsmedchemlett.2c00150

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  5 in total

Review 1.  Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.

Authors:  Lele Zhang; Jifa Zhang; Jiaxing Wang; Changyu Ren; Pan Tang; Liang Ouyang; Yuxi Wang
Journal:  Eur J Med Chem       Date:  2022-02-03       Impact factor: 6.514

Review 2.  Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer.

Authors:  Stepana Boukalova; Sona Hubackova; Mirko Milosevic; Zuzana Ezrova; Jiri Neuzil; Jakub Rohlena
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-03-06       Impact factor: 5.187

Review 3.  Metabolomics in cancer research and emerging applications in clinical oncology.

Authors:  Daniel R Schmidt; Rutulkumar Patel; David G Kirsch; Caroline A Lewis; Matthew G Vander Heiden; Jason W Locasale
Journal:  CA Cancer J Clin       Date:  2021-05-13       Impact factor: 286.130

Review 4.  Ferroptosis in cancer and cancer immunotherapy.

Authors:  Lei Zhao; Xiaoxue Zhou; Feng Xie; Lei Zhang; Haiyan Yan; Jun Huang; Chong Zhang; Fangfang Zhou; Jun Chen; Long Zhang
Journal:  Cancer Commun (Lond)       Date:  2022-02

Review 5.  Targeting Pyrimidine Metabolism in the Era of Precision Cancer Medicine.

Authors:  Wanyan Wang; Jiayan Cui; Hui Ma; Weiqiang Lu; Jin Huang
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.